Chemotherapy combined with bevacizumab for small cell lung cancer with brain metastases: A case report

Small cell lung cancer (SCLC) is a common and aggressive subtype of lung cancer. It is characterized by rapid growth and a high mortality rate. Approximately 10% of patients with SCLC present with brain metastases at the time of diagnosis, which is associated with a median survival of 5 mo. This stu...

Full description

Saved in:
Bibliographic Details
Published in:World journal of clinical cases 2024-01, Vol.12 (2), p.405-411
Main Authors: Yang, Hong-Yu, Xia, Yu-Qing, Hou, Yu-Jia, Xue, Peng, Zhu, Shi-Jie, Lu, Dian-Rong
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small cell lung cancer (SCLC) is a common and aggressive subtype of lung cancer. It is characterized by rapid growth and a high mortality rate. Approximately 10% of patients with SCLC present with brain metastases at the time of diagnosis, which is associated with a median survival of 5 mo. This study aimed to summarize the effect of bevacizumab on the progression-free survival (PFS) and overall survival of patients with brain metastasis of SCLC. A 62-year-old man was referred to our hospital in February 2023 because of dizziness and numbness of the right lower extremity without headache or fever for more than four weeks. The patient was diagnosed with limited-stage SCLC. He received 8 cycles of chemotherapy combined with maintenance bevacizumab therapy and achieved a PFS of over 7 mo. The combination of bevacizumab and irinotecan effectively alleviated brain metastasis in SCLC and prolonged PFS.
ISSN:2307-8960
2307-8960
DOI:10.12998/wjcc.v12.i2.405